Unless Teva is going to get approval soon or there is a less than strategic capital raise in the works,, I cannot believe MNTA is trading this low post approval. Maybe Sanofi's suit is holding the share price back. The portfolio is all green except MNTA.
Market Data 
Markets 
AI
